SK Biopharmaceuticals to make CES debut in January

SK Biopharmaceuticals will take part in CES 2023, the world's largest trade show for IT and electronics held in Las Vegas, to unveil its medical device for detecting signs of an epileptic seizure.

The company will be SK Group's first bio affiliate to participate at CES, which was formerly known as the Consumer Electronics Show.

Industry sources on Monday said the company will open a display at a joint booth run by its parent group at the trade show, which runs from Jan. 5-8. Spun off from SK Holdings (now SK Inc.) in 2011, SK Pharmaceuticals is returning to the event after 12 years and for the first time as a separate entity.

Leading the company's digital health care operations is senior manager Chey Yoon-chung, the eldest daughter of SK Group Chairman Chey Tae-won. Joining the company in 2017, she works for the strategic investment team.

In May this year, Chey Yoon-chung is known to have played a major role in the company's investment in digital treatment provider Cala Health of the US. An SK Pharmaceuticals source said her schedule at CES was not yet set.

The company in January's show will present its medical device for detecting and predicting epileptic seizures. Release of the gizmo's operating principles and algorithms could come as early as next month, and the objective is to launch clinical trials before the show opens.

SK Pharmaceuticals is the nation's only company to have two drugs with approval from the US Food and Drug Administration. The company exclusively uses its own technology and know-how in the entire process of product development, from finding promising drug candidates to holding clinical trials as well as approval and launch.

Write to Jeong-Min Nam at peux@hankyung.com